Menu
Wechat public account

Technologies

Bioinformatics
Whole-Omics Data Analysis System

The whole-omics data analysis system supports efficient automated analysis of various omics data from multiple sequencing platforms. This includes systems for whole-exome sequencing data analysis, 10x Genomics whole-genome data analysis, methylation chip data analysis, co-immunoprecipitation sequencing data analysis, transcriptome data analysis, RASL data analysis, and other omics data analysis platforms such as microbial amplicon sequencing data analysis and immune repertoire data analysis. The whole-omics data analysis system provides a platform for various omics technologies and lays the foundation for multi-omics joint analysis. By extracting and analyzing omics data from biological samples, it can explore and investigate omics data from multiple levels such as DNA, RNA, and metabolomics, providing ideas for solving biological problems. The omics data analysis system can standardize and automate the analysis process for each omics data through operational means, and meet diversified analysis needs through conventional and modular analyses. At the same time, the system is equipped with project management and task management modules, enabling users to comprehensively monitor and track projects and tasks in real-time for more convenient and efficient omics data research.



Clinical Pathogen Identification Based on Metagenomics

The MAPMI® data analysis and management cloud platform includes a data analysis management system and a report interpretation system. The data analysis management system achieves accurate detection and analysis of 16,109 viruses, 13,362 bacteria, 1,659 fungi, 270 parasites, and 2,500 drug resistance genes through a self-built high-quality and full-type pathogenic reference database. It utilizes cloud computing technology to enable rapid parallel analysis of sequencing data, completing one run (approximately 80GB) within 30 minutes. The MAPMI® data analysis algorithm exhibits good sensitivity and specificity in various types of clinical samples, making it particularly suitable for the analysis and auxiliary diagnosis of critically ill and difficult-to-diagnose infections. The report interpretation system integrates statistical analysis of data analysis results, enabling sample information management, cross-contamination determination, positive pathogen indicator screening and review, and clinical detection report generation.



Pharmacogenomics
Pharmacogenomics is based on functional genomics and molecular pharmacology, combined with pharmacokinetics and pharmacodynamics, to analyze the impact of genetic variations on drug responses. It helps guide clinicians in selecting appropriate drug formulations and dosages based on individual patient genetic characteristics to obtain optimal clinical medication guidance. The pharmacogenomics data platform mainly addresses precise medication interpretation based on individual patient genetic information, thereby assisting doctors in selecting the best treatment approach. Currently, the pharmacogenomics data platform includes two main application directions: a decision support system for oncology medication treatment and a precise medication interpretation system for mental illnesses.

The oncology medication treatment decision support system (OncoPDSS) consists of a data platform, analysis platform, and application platform. The data platform collects and organizes information on oncology medication guidance, including drug instructions and authoritative clinical guidelines such as NCCN. The analysis platform enables online analysis and annotation of genetic testing data. The application platform utilizes the knowledge data from the data platform to provide precise medication interpretation of genetic testing data from the analysis platform, generating a precise oncology medication interpretation report to assist clinicians in precise treatment of cancer patients.

The Mental Disease Precision Medication Interpretation System (MDPMS) generates interpretive reports on precision medication for mental illness based on a drug knowledge base, combined with basic patient information and genetic variation data, to provide personalized medication guidance. The drug knowledge base collects and organizes various types of medication evidence, including pharmacogenomic evidence, drug specifications, and clinical trial information. The MDPMS integrates multiple types of evidence to determine the list of usable, prohibited, and cautiously used drugs, and provides clinical trial information, gene-drug association information, etc., facilitating clinicians to comprehensively determine and select the optimal treatment.


Copyright © 2000-2023博奥生物集团有限公司 京ICP备14023013号-3

《互联网药品信息服务资格证书》: (京) - 非经营性-2016-0047 京公网安备11011402013114号